Global Atherosclerosis Drugs Market Is Projected To Exhibit Expansion At 2.3% CAGR Over The Next Ten Years

Published April 25, 2023

Atherosclerosis is a condition in which the arteries become narrow and hardened due to the buildup of fatty deposits and other substances. This can lead to a range of cardiovascular diseases, including heart attack and stroke. The market for drugs used to treat atherosclerosis is a significant one, and is driven by factors such as the aging population and the increasing incidence of lifestyle diseases such as obesity and diabetes. Some of the key drugs used to treat atherosclerosis include statins, which lower cholesterol levels and reduce the risk of cardiovascular events; antiplatelet agents, which prevent blood clots from forming and reduce the risk of heart attack and stroke; and angiotensin-converting enzyme (ACE) inhibitors, which help to lower blood pressure and reduce the risk of heart failure. The market for atherosclerosis drugs is highly competitive, with a number of major players including Pfizer, AstraZeneca, and Sanofi. These companies are continually investing in research and development to create new and improved drugs, as well as working to expand their market reach through partnerships and acquisitions.

The global market for atherosclerosis drugs is expected to continue to grow in the coming years, driven by factors such as the increasing prevalence of cardiovascular disease, the rise of personalized medicine, and the development of new and innovative treatment options. However, the market also faces challenges such as increasing competition, regulatory hurdles, and the high cost of drug development and commercialization.

This Atherosclerosis Drugs market research study is market-focused and provides a thorough review of the market and its potential moving forward. The study’s crucial and important data make it an extremely important tool for specialists, analysts, and managers to prepare for accessing analysis by professionals in the sector. The global Atherosclerosis Drugs market research offers a thorough study of the data on the size of the global market and development projections from 2018 to 2028. Complete details on the major global manufacturers and suppliers of the market are also included in this Atherosclerosis Drugs market study.

Get a Free Sample PDF of this Research Report

This Atherosclerosis Drugs market research report provides the ideal insight for a thorough market assessment by shedding light on the most recent technological developments, forthcoming business possibilities, market restraint factors, and threats. It covers regionally specific industrial contexts as well. Sources of raw materials, competitive environment, and regulatory framework that may affect the industry. The industry supply chain’s market size is planned using top-to-bottom and bottom-to-top techniques.

Key findings of the Atherosclerosis Drugs market study:

  • The report provides a present market outlook on Atherosclerosis Drugs. Additionally, the Atherosclerosis Drugs market share is anticipated to grow with a CAGR of 2.3% in the forecast period.
  • Regional breakdown of the Atherosclerosis Drugs market based on predefined taxonomy.
  • Innovative manufacturing processes implemented by Atherosclerosis Drugs vendors in detail.
  • Region-wise and country-wise fragmentation of the Atherosclerosis Drugs market to grasp the revenue, and growth outlook in these areas.
  • Changing preferences among consumers across various regions and countries.
  • Factors (Positive and Negative) impacting the growth of the global Atherosclerosis Drugs market.
  • Atherosclerosis Drugs price, market share, and Trends forecast for assessment period 2023-2033

Cholesterol-lowering Medication Sales to Soar Over Decade

Cholesterol-lowering medication sales have been steadily increasing over the past decade due to the growing awareness of the importance of managing cholesterol levels for overall health and reducing the risk of heart disease. With the aging population and increasing rates of obesity and other risk factors for heart disease, it is likely that the demand for cholesterol-lowering medications will continue to rise.

Additionally, new medications and treatment options for managing cholesterol levels are continually being developed and approved by regulatory agencies, such as the FDA. These innovations may also contribute to an increase in sales of cholesterol-lowering medications over the next decade.

However, it’s worth noting that there could also be potential challenges and barriers to this trend, such as the rising costs of healthcare and medication, changing healthcare policies, and potential shifts in consumer behavior and preferences. Therefore, while it’s possible that cholesterol-lowering medication sales could continue to soar over the next decade, it’s also important to consider the broader context and factors that could impact this trend.

Competitive landscape analysis

To maximise their sales potential and address expanding demand in the Asia Pacific area, leading atherosclerosis drug suppliers are focused on the development of generic pharmaceuticals.

  • Cadila Pharmaceuticals, an Indian pharmaceutical company, announced the launch of generic versions of sitagliptin in August 2022. Sitagliptin is a DPP-4 inhibitor used to treat hyperglycemia, which is known to lead to complications such as heart attacks, stroke, and atherosclerosis. For type 2 diabetes, generic versions were marketed in India under the brand names Sitenali and Jankey.

Some of the leading companies operating in the market are :

  • Merck & Co. Inc.
  • Sanofi
  • Hoffmann La-Roche Ltd.
  • Bayer AG
  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline Plc
  • Janssen Global Services LLC
  • Amgen Inc.
  • Mylan N.V.

What insights does the Atherosclerosis Drugs report provide to the readers?

  • Atherosclerosis Drugs fragmentation on the basis of product type, end use, and region.
  • Comprehensive assessment of upstream starting materials, downstream demand, and present market landscape.
  • Collaborations, R&D projects, acquisitions, and product launches of each Atherosclerosis Drugs
  • Various regulations imposed by the governments on the consumption of Atherosclerosis Drugs in detail.

Key Segments of Atherosclerosis Drugs Industry Research

·         By Drug Class :

    • Anti-platelet Medications
    • Cholesterol-lowering Medications
    • Fibric Acid and Omega-3 Fatty Acid Derivatives
    • Beta Blockers
    • Angiotensin-converting Enzyme (ACE) Inhibitors
    • Calcium Channel Blockers
    • Diuretics
    • Others

·         By Distribution Channel :

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

·         By Region :

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

For in-depth competitive analysis, Buy Now –


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583


This Press Release has been written with the intention of providing accurate market information which will enable our readers to make informed strategic investment decisions. If you notice any problem with this content, please feel free to reach us on


Xherald is passionate about offering extensive coverage of global business news. Dedicated to creating every participant's notification, it reaches its own reader. Daily our experts offer fresh relevant information regarding what is actually occurring in Markets as well as Business. Our headlines are actually swiftly paced and extensive. Our distributor directory connects you with brand new products or services and its market situation from the most effective companies around the planet. Xherald is driven by its 500+ contributors coming from around the world. Xherald provides local as well as global market intelligence information coverage in sectors ranging from healthcare, IOT, chemicals and 17 more sectors. Our updates are quickly paced and detailed. The news we present is actually a mix of authentic content, community contributions and curated headlines announcements. All of the updates our company supplies must pass a strict criterion of genuineness, relevance and significance to our readers.